{Reference Type}: Journal Article
{Title}: A case of omalizumab as a successful treatment for telangiectasia macularis eruptiva perstans.
{Author}: Mortimore AM;Barsoum R;Lambie D;McMeniman E;
{Journal}: Australas J Dermatol
{Volume}: 0
{Issue}: 0
{Year}: Jul 2021 27
{Factor}: 2.481
{DOI}: 10.1111/ajd.13674
{Abstract}: Treatment for telangiectasia macularis eruptiva perstans (TMEP) is often challenging due to lack of an established first-line therapy and as such is primarily focused on symptomatic relief. Omalizumab shows promise as a potential therapy for mast cell disorders; however, its efficacy in TMEP is yet to be established. This case describes a 72-year-old woman with chronic refractory TMEP achieving symptomatic remission within 4 months of commencing omalizumab therapy.